Catalyst Wire Dossier Catalyst Wire Dossier

Welireg

belzutifan · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

20 regulatory and trial events tracked for Welireg, covering 2021-08-13 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) [Phase 2]

See pricing